FDA Clears New Centiloid Scoring and Tau PET Quantification Tools

The Food and Drug Administration (FDA) has granted 510(k) clearance of Centiloid scoring and tau positron emission tomography (PET) quantification, features that are available with the syngo.PET Cortical Analysis software (Siemens Healthineers).

Employing a 100-point scale for the assessment of beta-amyloid plaque, the Centiloid scoring feature can be utilized with three different beta-amyloid PET radiopharmaceuticals approved to detect Alzheimer’s disease, according to Siemens Healthineers.

The company said using the tau PET quantification feature in combination with the radiopharmaceutical flortaucipir (Tauvid. Eli Lilly) enables quantification of the distribution and density of tau protein tangles on brain PET scans.

“The ability to quantify the buildup of amyloid plaque and tau protein in the brains of Alzheimer’s disease patients can provide clinicians with important diagnostic and staging information pertaining to the disease,” said Martin Cordell, Ph.D., the director of product lifecycle management at Siemens Healthineers Molecular Imaging.“The addition of Centiloid scoring and tau PET quantification features to our syngo.PET Cortical Analysis software fortifies our integrated and comprehensive portfolio for detection, diagnosis, monitoring, and follow-up related to Alzheimer’s disease.”